Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

Journal Article · Tue Jan 01 00:00:00 EST 2013 · PLoS ONE

DOI:https://doi.org/10.1371/journal.pone.0054531· OSTI ID:1095631

McLaughlin, Mark F ^[1]; Woodward, Jonathan ^[1]; Boll, Rose Ann ^[1]; Wall, Jonathan ^[2]; Kennel, Steve J ^[1]; Mirzadeh, Saed ^[1]; Robertson, David J. ^[3]

---

1. ORNL
2. University of Tennessee, Knoxville (UTK)
3. University of Missouri

Targeted radiotherapies maximize cytotoxicty to cancer cells. In vivo generators such as 225Ac, which emits four particles in its decay chain, can significantly amplify the radiation dose delivered to the target site. However, renal dose from unbound 213Bi escaping during the decay process limits the dose of 225Ac that can be administered. Traditional chelating moieties are unable to sequester the radioactive daughters because of the high recoil energy from alpha particle emission. To counter this, we demonstrate that an engineered multilayered nanoparticle-antibody conjugate can both deliver radiation and contain the decay daughters of the in vivo -generator 225Ac while targeting biologically relevant receptors. These multi-shell nanoparticles combine the radiation resistance of crystalline lanthanide phosphate to encapsulate and contain 225Ac and its radioactive decay daughters, the magnetic properties of gadolinium phosphate for easy separation, and established surface chemistry of gold for attachment of nanoparticles to targeting antibodies.

• Research Organization: Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States). Center for Nanophase Materials Sciences (CNMS)
• Sponsoring Organization: USDOE Office of Science (SC)
• DOE Contract Number: DE-AC05-00OR22725
• OSTI ID: 1095631
• Journal Information: PLoS ONE, Vol. 8, Issue 1; ISSN 1932-6203
• Publisher: Public Library of Science
• Country of Publication: United States
• Language: English

Related Subjects

Targeted Alpha Radiotherapy
actinium-225
Nanoparticles
Lanthanide Phosphate